192 related articles for article (PubMed ID: 26302797)
1. PLK1 Inhibition: Prospective Role for the Treatment of Pediatric Tumors.
Pezuk JA; Valera ET; Brassesco MS
Curr Drug Targets; 2016; 17(14):1661-1672. PubMed ID: 26302797
[TBL] [Abstract][Full Text] [Related]
2. Polo-like kinase 1, on the rise from cell cycle regulation to prostate cancer development.
Luo J; Liu X
Protein Cell; 2012 Mar; 3(3):182-97. PubMed ID: 22447658
[TBL] [Abstract][Full Text] [Related]
3. Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.
Nihal M; Stutz N; Schmit T; Ahmad N; Wood GS
Cell Cycle; 2011 Apr; 10(8):1303-11. PubMed ID: 21436619
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1.
Berg A; Berg T
Chembiochem; 2016 Apr; 17(8):650-6. PubMed ID: 26662918
[TBL] [Abstract][Full Text] [Related]
5. Small-molecular, non-peptide, non-ATP-competitive polo-like kinase 1 (Plk1) inhibitors with a terphenyl skeleton.
Mita Y; Noguchi-Yachide T; Ishikawa M; Hashimoto Y
Bioorg Med Chem; 2013 Feb; 21(3):608-17. PubMed ID: 23276450
[TBL] [Abstract][Full Text] [Related]
6. Plk1-targeted small molecule inhibitors: molecular basis for their potency and specificity.
Murugan RN; Park JE; Kim EH; Shin SY; Cheong C; Lee KS; Bang JK
Mol Cells; 2011 Sep; 32(3):209-20. PubMed ID: 21809214
[TBL] [Abstract][Full Text] [Related]
7. Polo-like Kinase 1 as an emerging drug target: structure, function and therapeutic implications.
Shakeel I; Basheer N; Hasan GM; Afzal M; Hassan MI
J Drug Target; 2021 Feb; 29(2):168-184. PubMed ID: 32886539
[TBL] [Abstract][Full Text] [Related]
8. Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition.
Kreis NN; Louwen F; Zimmer B; Yuan J
Oncotarget; 2015 Mar; 6(9):6611-26. PubMed ID: 25483104
[TBL] [Abstract][Full Text] [Related]
9. Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis.
Gilmartin AG; Bleam MR; Richter MC; Erskine SG; Kruger RG; Madden L; Hassler DF; Smith GK; Gontarek RR; Courtney MP; Sutton D; Diamond MA; Jackson JR; Laquerre SG
Cancer Res; 2009 Sep; 69(17):6969-77. PubMed ID: 19690138
[TBL] [Abstract][Full Text] [Related]
10. Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells.
Chapagai D; Ramamoorthy G; Varghese J; Nurmemmedov E; McInnes C; Wyatt MD
J Med Chem; 2021 Jul; 64(14):9916-9925. PubMed ID: 34210138
[TBL] [Abstract][Full Text] [Related]
11. Developments of polo-like kinase 1 (Plk1) inhibitors as anti-cancer agents.
Li S; Zhang Y; Xu W
Mini Rev Med Chem; 2013 Dec; 13(14):2014-25. PubMed ID: 24160708
[TBL] [Abstract][Full Text] [Related]
12. Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy.
Lee KS; Burke TR; Park JE; Bang JK; Lee E
Trends Pharmacol Sci; 2015 Dec; 36(12):858-877. PubMed ID: 26478211
[TBL] [Abstract][Full Text] [Related]
13. Polo-like kinases inhibitors.
Garuti L; Roberti M; Bottegoni G
Curr Med Chem; 2012; 19(23):3937-48. PubMed ID: 22709006
[TBL] [Abstract][Full Text] [Related]
14. RNAi prodrugs decrease elevated mRNA levels of Polo-like kinase 1 in ex vivo cultured primary cells from pediatric acute myeloid leukemia patients.
Kolosenko I; Goroshchuk O; Vidarsdottir L; Björklund AC; Dowdy SF; Palm-Apergi C
FASEB J; 2021 May; 35(5):e21476. PubMed ID: 33788972
[TBL] [Abstract][Full Text] [Related]
15. Developing polo-like kinase 1 inhibitors.
Huang X; Xie Z; Liao C
Future Med Chem; 2020 May; 12(10):869-871. PubMed ID: 32233804
[No Abstract] [Full Text] [Related]
16. Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma.
Evans RP; Dueck G; Sidhu R; Ghosh S; Toman I; Loree J; Bahlis N; Klimowicz AC; Fung J; Jung M; Lai R; Pilarski LM; Belch AR; Reiman T
Leuk Res; 2011 Dec; 35(12):1637-43. PubMed ID: 21816470
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions.
Reindl W; Yuan J; Krämer A; Strebhardt K; Berg T
Chem Biol; 2008 May; 15(5):459-66. PubMed ID: 18482698
[TBL] [Abstract][Full Text] [Related]
18. Targeting polo-like kinase 1 for cancer therapy.
Strebhardt K; Ullrich A
Nat Rev Cancer; 2006 Apr; 6(4):321-30. PubMed ID: 16557283
[TBL] [Abstract][Full Text] [Related]
19. Small-molecule inhibitors for targeting polo-like kinase 1.
Kolosenko I; Palm-Apergi C
Future Med Chem; 2020 Aug; 12(16):1457-1460. PubMed ID: 32638616
[No Abstract] [Full Text] [Related]
20. Polo-like kinase controls vertebrate spindle elongation and cytokinesis.
Brennan IM; Peters U; Kapoor TM; Straight AF
PLoS One; 2007 May; 2(5):e409. PubMed ID: 17476331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
